Tenpoint Therapeutics secured FDA approval for its presbyopia eye drop and announced $235 million in combined debt and equity to support commercialization. The company positioned the product as a differentiated topical alternative to reading glasses and competitor offerings from AbbVie and others, and said funding will bankroll marketing and market access activities. The approval places Tenpoint into a crowded but growing ocular therapeutics market where coverage, physician adoption and real‑world performance will determine uptake. The financing and regulatory milestone de‑risks commercialization but raises the stakes for rapid market execution against established players.